Abstract
Cardiomyopathies represent a heterogeneous group of heart muscle diseases that are a major cause of morbidity and mortality. Classification schemes for cardiomyopathy have been complex, and efforts have been made to classify the disease states based on myocardial characteristics and etiologies. The etiology, diagnosis, and management of dilated cardiomyopathy (DCM), restrictive/infiltrative cardiomyopathy, and hypertrophic cardiomyopathy (HCM) are the subject of this chapter and several features of each form of cardiomyopathy are highlighted in Table 17-1.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ACE:
-
Angiotensin converting enzyme
- AF:
-
Atrial fibrillation
- ANA:
-
Anti-nuclear antibody
- AR:
-
Aortic regurgitation
- ARB:
-
Angiotensin receptor blocker
- ARVC:
-
Arrhythmogenic right ventricular cardiomyopathy
- BNP:
-
B-type natriuretic peptide
- CAD:
-
Coronary artery disease
- CMV:
-
Cytomegalovirus
- CRT:
-
Cardiac resynchronization therapy
- CT:
-
Computed tomography
- CXR:
-
Chest x-ray
- DCM:
-
Dilated cardiomyopathy
- E’:
-
Early peak diastolic tissue velocity
- ECG:
-
Electrocardiogram
- HCM:
-
Hypertrophic cardiomyopathy
- HIV:
-
Human immunodeficiency virus
- HOCM:
-
Hypertrophic obstructive cardiomyopathy
- ICD:
-
Implantable cardioverter defibrillator
- LV:
-
Left ventricle or left ventricular
- LVEF:
-
Left ventricular ejection fraction
- LVH:
-
Left ventricular hypertrophy
- LVOT:
-
Left ventricular outflow tract
- MR:
-
Mitral regurgitation
- MRI:
-
Magnetic resonance imaging
- NTproBNP:
-
N-terminal pro B-type natriuretic peptide
- RV:
-
Right ventricle or right ventricular
- SAM:
-
Systolic anterior motion
- SCD:
-
Sudden cardiac death
- SPEP:
-
Serum protein electrophoresis
References
Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med. 2011;364(17):1643–56.
McMurray JJ. Systolic heart failure. N Engl J Med. 2010;362(3):228–38.
Maron BJ, Towbin JA, Gaetano T, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of cardiomyopathies. Circulation. 2006;113:1807–16.
Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077–84.
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. Circulation. 2009;119(14):e391–479.
Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116(19):2216–33.
Hershberger RE, Lindenfeld J, Mestroni L, Seidman CE, Taylor MRG, Towbin JA. Genetic evaluation of cardiomyopathy – a Heart Failure Society of America practice guideline. J Card Fail. 2009;15:83–97.
Seward JB, Casaclang-Verzosa G. Infiltrative cardiovascular diseases: cardiomyopathies that look alike. J Am Coll Cardiol. 2010;55(17):1769–79.
Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007;50(22):2101–10.
Kim JS, Judson MA, Donnino R, Gold M, Cooper Jr LT, Prystowsky EN, et al. Cardiac sarcoidosis. Am Heart J. 2009;157(1):9–21.
Ammash NM, Seward JB, Bailey KR, Edwards WD, Tajik AJ. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation. 2000;101(21):2490–6.
Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308–20.
Maron BJ. Distinguishing hypertrophic cardiomyopathy from athlete’s heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening. Br J Sports Med. 2009;43(9):649–56.
Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation. 2010;121(3):445–56.
Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and Âtreatment of hypertrophic cardiomyopathy. Circulation. 2011;124(24):2761–96.
Mitchell JH, Haskell W, Snell P, Van Camp SP. Task force 8: classification of sports. J Am Coll Cardiol. 2005;45(8):1364–7.
Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118(2):131–9.
Chang SM, Nagueh SF, Spencer 3rd WH, Lakkis NM. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol. 2003;42(2):296–300.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
DCM (AVI 14959 kb)
Amyloid (AVI 17528 kb)
HCM (AVI 9632 kb)
Rights and permissions
Copyright information
© 2014 Springer-Verlag London
About this chapter
Cite this chapter
Weiner, R.B., Baggish, A.L., Baggish, A.L. (2014). Dilated, Restrictive/Infiltrative, and Hypertrophic Cardiomyopathies. In: Gaggin, H., Januzzi, Jr., J. (eds) MGH Cardiology Board Review. Springer, London. https://doi.org/10.1007/978-1-4471-4483-0_17
Download citation
DOI: https://doi.org/10.1007/978-1-4471-4483-0_17
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-4482-3
Online ISBN: 978-1-4471-4483-0
eBook Packages: MedicineMedicine (R0)